A Phase 3 Open-Label, Randomized Study of LOXO-305 versus Investigator Choice of BTK Inhibitor in Patients with Previously Treated BTK Inhibitor Nave Mantle Cell Lymphoma (BRUIN MCL-321)
Sponsor: |
Loxo Oncology, Inc. |
Enrolling: |
Male and Female Patients |
IRB Number: |
AAAT6851 |
U.S. Govt. ID: |
NCT04662255 |
Contact: |
Research Nurse Navigator: 212-342-5162 / cancerclinicaltrials@cumc.columbia.edu |
This research study is being done to test the effectiveness and safety of an investigational treatment called LOXO-305. LOXO-305 is an investigational (or experimental) drug that may treat certain cancers like leukemia and lymphomas, including, mantle cell lymphoma (MCL). These cancers are dependent on or addicted to a protein made by the cancers called BTK. LOXO-305 is a BTK inhibitorit is designed to block both normal and mutated forms of BTK in these cancers.
Investigator
Andrew Lipsky, MD
Are you at least 18 years old? |
Yes |
No |
Are you able to swallow oral study medication? |
Yes |
No |
Have you had major surgery within 4 weeks prior to study? |
Yes |
No |
Is your life expectancy greater than 3 months? |
Yes |
No |